Endocrinology

• Meeting News Coverage

• Investigational drug improves symptoms of Cushing’s disease

• June 5, 2011
• ENDO 2011
  BOSTON — Phase 3 data from the PASPORT-CUSHINGS trial show significantly reduced cortisol levels and improved quality of life in patients with...More »

• Meeting News Coverage

• Weight-based dosing regimen for glucagon stimulation test more reliable than fixed-dose

• June 5, 2011
• ENDO 2011
  BOSTON — Using a weight-based regimen of the glucagon stimulation test may be more favorable than using a fixed-dose regimen in evaluating...More »

• Meeting News Coverage

• New guidelines address diagnosis, treatment of pituitary apoplexy

• Endocrine Today, June 2011
• Society for Endocrinology BES 2011
  Pituitary apoplexy should be treated immediately by specialist medical teams to avoid permanent damage to eye nerves and...More »

• FDA approves sunitinib for pancreatic neuroendocrine tumors

• May 20, 2011
• Sunitinib malate has received FDA approval as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors in...More »

• Guidelines issued for evaluation, management of pituitary incidentalomas

• May 17, 2011
• The evaluation and treatment of pituitary incidentalomas, a previously unsuspected pituitary lesion discovered on an unrelated imaging study, is the...More »

• FDA approves everolimus for pancreatic neuroendocrine tumors

• May 6, 2011
• The FDA has approved everolimus to treat patients with progressive pancreatic neuroendocrine tumors that cannot be removed by surgery or that have...More »

• Meeting News Coverage Perspective

• Octreotide hydrogel implant safe, effective in acromegaly

• Endocrine Today, May 2011
• American Association of Clinical Endocrinologists 20th Annual Meeting
  SAN DIEGO — Patients with acromegaly who received a 52-mg octreotide hydrogel implant...More »

• Imaging Analysis

• Case of an asymptomatic pituitary mass

• Endocrine Today, May 2011
  Stephanie L. Lee, MD, PhD
• A 45-year-old Asian woman was referred for the evaluation of a pituitary mass. The patient was well, with no significant past medical history. She...More »

• ODAC approves everolimus for treatment of pancreatic neuroendocrine tumors

• April 12, 2011
• The FDA’s Oncologic Drugs Advisory Committee voted unanimously today to approve a supplemental new drug application from Novartis to use everolimus...More »

• ODAC approves indication for sunitinib in treatment of PNET

• April 12, 2011
• The FDA’s Oncologic Drugs Advisory committee voted 8-2 today in support of the use of Pfizer’s sunitinib in the treatment of unresectable...More »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!